AIM ImmunoTech Inc. — Director's Dealing 2018

Jul 20, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HEMISPHERX BIOPHARMA INC (HEB)
CIK: 0000946644
Period of Report: 2018-07-18

Reporting Person: APPELROUTH STEWART (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-07-18	Options to buy Common Stock	$0.31	A	98098	Acquired	2028-07-18	Common Stock (98098)	Direct

Footnotes

F1: This option is being issued to senior management for a voluntary 100% deferral of Directors Fees.